H. Döhner

2.7k total citations · 1 hit paper
27 papers, 1.8k citations indexed

About

H. Döhner is a scholar working on Genetics, Pathology and Forensic Medicine and Public Health, Environmental and Occupational Health. According to data from OpenAlex, H. Döhner has authored 27 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Genetics, 14 papers in Pathology and Forensic Medicine and 8 papers in Public Health, Environmental and Occupational Health. Recurrent topics in H. Döhner's work include Chronic Lymphocytic Leukemia Research (17 papers), Lymphoma Diagnosis and Treatment (14 papers) and Acute Lymphoblastic Leukemia research (8 papers). H. Döhner is often cited by papers focused on Chronic Lymphocytic Leukemia Research (17 papers), Lymphoma Diagnosis and Treatment (14 papers) and Acute Lymphoblastic Leukemia research (8 papers). H. Döhner collaborates with scholars based in Germany, United Kingdom and Austria. H. Döhner's co-authors include Stephan Stilgenbauer, Peter Lichter, Martin Bentz, Axel Benner, Konstanze Fischer, Richard F. Schlenk, W. Hunstein, Johannes Coy, Daniela Diehl and Albert J. Poustka and has published in prestigious journals such as Blood, JNCI Journal of the National Cancer Institute and Leukemia.

In The Last Decade

H. Döhner

27 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias

1995 576 citations H. Döhner, Konstanze Fischer et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
H. Döhner Germany	19	1.1k	850	546	507	465	27	1.8k
Paul Evans United Kingdom	21	994 0.9×	889 1.0×	442 0.8×	484 1.0×	834 1.8×	54	1.9k
R. D. Gascoyne Canada	24	599 0.5×	925 1.1×	535 1.0×	389 0.8×	347 0.7×	39	1.9k
Monica Else United Kingdom	22	1.6k 1.4×	1.2k 1.4×	428 0.8×	712 1.4×	320 0.7×	42	2.0k
Dominique Leroux France	24	660 0.6×	912 1.1×	880 1.6×	516 1.0×	672 1.4×	74	2.4k
Ilaria Del Giudice Italy	24	1.5k 1.3×	1.3k 1.5×	331 0.6×	764 1.5×	305 0.7×	82	1.9k
Evelyne Callet‐Bauchu France	26	1.1k 1.0×	1.8k 2.1×	542 1.0×	406 0.8×	283 0.6×	62	2.6k
HM Golomb United States	22	877 0.8×	665 0.8×	451 0.8×	488 1.0×	874 1.9×	47	2.0k
Monica Messina Italy	20	845 0.8×	1.1k 1.3×	803 1.5×	455 0.9×	503 1.1×	49	2.2k
Andreas Bühler Germany	21	2.2k 1.9×	1.6k 1.9×	599 1.1×	920 1.8×	428 0.9×	47	2.7k
James A. L. Fenton United Kingdom	16	695 0.6×	693 0.8×	522 1.0×	486 1.0×	402 0.9×	31	1.4k

Countries citing papers authored by H. Döhner

Since Specialization

Citations

This map shows the geographic impact of H. Döhner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Döhner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Döhner more than expected).

Fields of papers citing papers by H. Döhner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Döhner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Döhner. The network helps show where H. Döhner may publish in the future.

Co-authorship network of co-authors of H. Döhner

This figure shows the co-authorship network connecting the top 25 collaborators of H. Döhner. A scholar is included among the top collaborators of H. Döhner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Döhner. H. Döhner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tausch, Eugen, Jasmin Bahlo, Sandra Robrecht, et al.. (2019). GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORABMUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY Best abstract submitted by a young investigator / travel grant recipient. Hematological Oncology. 37(S2). 84–86. 2 indexed citations

Vasyutina, Elena, Jorge Bouças, Johannes Bloehdorn, et al.. (2015). The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL. Leukemia. 29(10). 2003–2014. 14 indexed citations

Sun, Su Ming, Lars Bullinger, Eric M. Bindels, et al.. (2015). Aberrant expression of miR-9/9* in myeloid progenitors inhibits neutrophil differentiation by post-transcriptional regulation of ERG. Leukemia. 30(1). 229–237. 22 indexed citations

Goede, Valentin, Paula Cramer, R. Busch, et al.. (2014). Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica. 99(6). 1095–1100. 72 indexed citations

Sun, Su Ming, Veronika Ročková, Lars Bullinger, et al.. (2012). The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML. Leukemia. 27(1). 100–106. 48 indexed citations

Giannopoulos, Krzysztof, Anna Dmoszyńska, Małgorzata Kowal, et al.. (2010). Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia. Leukemia. 24(4). 798–805. 41 indexed citations

Kienle, Dirk, Axel Benner, Dirk Winkler, et al.. (2009). Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia. Haematologica. 95(1). 102–109. 24 indexed citations

Weßendorf, Swen, Thomas F.E. Barth, Andreas Viardot, et al.. (2007). Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH). Leukemia. 21(12). 2463–2469. 50 indexed citations

Stilgenbauer, Stephan, Sandrine Sander, Lars Bullinger, et al.. (2007). Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica. 92(9). 1242–1245. 153 indexed citations

10.

Schaich, Markus, R. Schlenk, Haifa Kathrin Al‐Ali, et al.. (2007). Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. Haematologica. 92(6). 763–770. 35 indexed citations

11.

Seiffert, Martina, Stephan Stilgenbauer, H. Döhner, & Peter Lichter. (2007). Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids. Leukemia. 21(9). 1977–1983. 57 indexed citations

12.

Döhner, H., et al.. (2006). Risk Stratification in Chronic Lymphocytic Leukemia. Seminars in Oncology. 33(2). 186–194. 56 indexed citations

13.

Stilgenbauer, S., Alexander Kröber, Dirk Winkler, et al.. (2005). Efficacy of subcutaneous Alemtuzumab (Campath-1H) in genetic high-risk, fludarabine-refractory CLL: CLL2H study of the German CLL Study Group (GCLLSG). mediaTUM (Technical University of Munich). 18 indexed citations

14.

Kuendgen, A., Barbara Hildebrandt, Floyd E. Fox, et al.. (2005). P-112 Results of a phase II trial with valproic acid (VPA) alone or in combination with all-trans-retinoic acid (ATRA) in 71 patients with myelodysplastic syndromes or SAML/MDS. Leukemia Research. 29. S66–S66. 1 indexed citations

15.

Böttcher, Sebastian, Matthias Ritgen, Christiane Pott, et al.. (2004). Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia. 18(10). 1637–1645. 67 indexed citations

16.

Marcucci, Guido, MA Caligiuri, H. Döhner, et al.. (2001). Quantification of CBFβ/MYH11 fusion transcript by Real Time RT-PCR in patients with INV(16) acute myeloid leukemia. Leukemia. 15(7). 1072–1080. 95 indexed citations

17.

Gahn, B., G. Brittinger, Gottfried Dölken, et al.. (2000). Multicenter Phase II Study of Oral Idarubicin in Treated and Untreated Patients with B-Chronic Lymphocytic Leukemia. Leukemia & lymphoma. 37(1-2). 169–173. 2 indexed citations

18.

Fischer, Konstanze, Catharina Scholl, Stefan Fröhling, et al.. (1996). Design and validation of DNA probe sets for a comprehensive interphase cytogenetic analysis of acute myeloid leukemia. Blood. 88(10). 3962–3971. 64 indexed citations

19.

Döhner, H., Konstanze Fischer, Martin Bentz, et al.. (1995). p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 85(6). 1580–1589. 576 indexed citations breakdown →

20.

Döhner, H., Anthony D. Ho, J. Thaler, et al.. (1993). Pentostatin in Prolymphocytic Leukemia: Phase II Trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group. JNCI Journal of the National Cancer Institute. 85(8). 658–662. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact